IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease wi
Go back to IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease wi| Johnson & Johnson (NYSE: JNJ) | Delayed: 238.70 +7.41 (3.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $231.29 | 52 Week High | $126.07 | |||
| Open | $235.64 | 52 Week Low | $94.28 | |||
| Day High | $238.99 | P/E | 49.63 | |||
| Day Low | $234.35 | EPS | $4.81 | |||
| Volume | 6,131,998 | |||||
